ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תמיסה להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes mellitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes melitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes melitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of diabetes.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of diabetes.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

vitamed pharmaceutical industries ltd - dexchlorpheniramine maleate; pseudoephedrine hydrochloride - סירופ - dexchlorpheniramine maleate 1 mg / 5 ml; pseudoephedrine hydrochloride 25 mg / 5 ml - pseudoephedrine, combinations - pseudoephedrine, combinations - relief of congestion in the respiratory tract due to allergy.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - אבקה לשאיפה - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of severe and moderate reversible obstructive airways disease ( road) , including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. extension of copd indication for seretide diskus:seretide is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - אבקה לשאיפה - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of severe and moderate reversible obstructive airways disease ( road) , including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. extension of copd indication for seretide diskus:seretide is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.